Mirvetuximab soravtansine
- Generic Name
- Mirvetuximab soravtansine
- Brand Names
- Elahere
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1453084-37-1
- Unique Ingredient Identifier
- 98DE7VN88D
- Background
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.
...
- Indication
Mirvetuximab soravtansine is indicated for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
...
- Associated Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Platinum Resistant Primary Peritoneal Cancer, Platinum drug resistant Fallopian tube cancer
- Associated Therapies
- -
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of ...
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.